Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Clinical and economic impact of five-year adherence to disease-modifying therapies in a commercially insured multiple sclerosis population.
Prescriptive Oriented Drug Analysis of Multiple Sclerosis Disease by LC-UV in Whole Human Blood.
Mapping search terms to review goals is essential.
Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2 Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis.
MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients.
Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
Is there A Genetic Correlation between Multiple Sclerosis and Cerebral Aneurysms?
Responsiveness of selected outcome measures of participation restriction and quality of life in patients with multiple sclerosis.
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations.
Outcomes After Early Administration of Plasma Exchange in Pediatric Central Nervous System Inflammatory Demyelination.
Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease.
Office immunotherapy in chronic inflammatoryh demyelinating polyneuropathy and multifocal motor neuropathy.
Alarmin' Immunologists: IL-33 as a Putative Target for Modulating T Cell-Dependent Responses.
Tablet-based screening improves continence management in multiple sclerosis.
Examining vascular remodeling in the hypoxic central nervous system.
Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Successful treatment of paroxysmal tonic spasms with topiramate in a patient with neuromyelitis optica.
Efficacy of rituximab in refractory neuromyelitis optica.
The Emerging Role of MitomiRs in the Pathophysiology of Human Disease.
Association of myelin peptide with vitamin D prevents autoimmune encephalomyelitis development.
Multiple sclerosis: Fatigue-a warning sign for multiple sclerosis?
Therapeutic Cleavage of Anti-Aquaporin-4 Autoantibody in Neuromyelitis Optica by an Igg-Selective Proteinase.
Unusual side effects of interferon Beta-1a in patient with multiple sclerosis.
Sodium accumulation is associated with disability and progression in multiple sclerosis: a 23na MRI study.
Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.
Pages
« first
‹ previous
…
661
662
663
664
665
666
667
668
669
…
next ›
last »